Abstracts tagged "rheumatoid arthritis"

Abstract Number: 140 • 2016 ACR/ARHP Annual Meeting
Relationship Between the Prevalence of Subclinical Tenosynovitis and Therapy in Patients with RA in Clinical Remission: Results from Italian Society of Rheumatology Study Group
Simone Parisi¹, Greta Carrara², Carlo Alberto Scirè^3,4, Alberto Batticciotto⁵, Emanuela Bellis⁶, Marco Canzoni⁷, Orazio De Lucia⁸, Ilaria Farina⁹, Carlo Venditti¹⁰, Annamaria Iagnocco^11,12 and Georgios Filippou¹³, ¹Department of Rheumatology, University Hospital Città Della Salute e della Scienza di Torino, Turin, Italy, ²Epidemiology Unit, Italian Society for Rheumatology, Milano, Italy, ³Epidemiology Unit -Italian Society for Rheumatology, Milano, Italy, ⁴Epidemiology Unit – Italian Society for Rheumatology (SIR), Milano, Italy, ⁵Rheumatology, L. Sacco University Hospital, Milano, Italy, ⁶Rheumatology, Ospedale Mauriziano, Turin, Italy, ⁷A.O. Sant'Andrea, Rome, Italy, ⁸Rheumatology, Orthopedic Institute Gaetano Pini, Milano, Italy, ⁹Rheumatology Unit AOU S.Anna, Ferrara, Italy, ¹⁰A.O. Rummo, Benevento, Italy, ¹¹Sapienza University of Rome, Rome, Italy, ¹²Sapienza University of Rome, Italy, Roma, Italy, ¹³University of Siena, Siena, Italy
Background/Purpose: This study is a sub-analysis of the data from the patient cohort of STARTER (The Sonographic Tenosynovitis Assessment in RheumaToid arthritis patiEnts in Remission)…
Abstract Number: 2174 • 2016 ACR/ARHP Annual Meeting
Effect of Anti-Rheumatic Treatment on Selenium Levels in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Gia Deyab¹, Ingrid Hokstad², Milada Cvancarova Småstuen³, Stefan Agewall⁴, Jon Elling Whist⁵ and Ivana Hollan^5,6,7,8, ¹Department of Medical Biochemistry, Innlandet Hospital Trust, Lillehammer, Norway, ²Lillehammer Hospitat for Rheumatic Diseases, Lillehammer, Norway, ³Institution of health care - Health science PhD program, Oslo and Akershus University College, Oslo, Norway, ⁴University of Oslo, Oslo, Norway, ⁵Innlandet Hospital Trust, Lillehammer, Norway, ⁶Brigham and Women’s Hospital, Boston, MA, ⁷Harvard Medical School, Boston, MA, ⁸Lillehammer Hospital for Rheumatic Diseases, Lillahammer, Norway
Background/Purpose: The cause of the increased cardiovascular risk in inflammatory rheumatic diseases (IRDs) is still unclear. Intriguingly, selenium-deficiency, which might be caused by poor diet or…
Abstract Number: 179 • 2016 ACR/ARHP Annual Meeting
CD11b+Gr1dimcells, Which Are Induced By GM-CSF Produced By Th17 and Group3 Innate Lymphoid Cell, May Facilitate the Progression of Pneumonitis in SKG Mice
Sho Sendo¹, Jun Saegusa¹, Takaichi Okano², Soshi Takahashi³ and Akio Morinobu¹, ¹Rheumatology and Clinical Immunology, Kobe University Graduate School of Medicine, Kobe, Japan, ²Rheumatology and Clinical immunology, Kobe University Graduate School of Medicine, Kobe, Japan, ³Department of Rheumatology and Clinical Immunology, Kobe University Graduate School of Medicine, Kobe, Japan
Background/Purpose: Rheumatoid lung disease is a prognostic factors of rheumatoid arthritis in human. The pathogenesis and the mechanism of rheumatoid lung disease is unclear. Zymosan…
Abstract Number: 2558 • 2016 ACR/ARHP Annual Meeting
Dissociation of the Inhibitory Apoptosis Stimulating Protein of p53 (iASPP) Binding with Transcription Factor p73 Induces Synovial Fibroblast Apoptosis in the Rheumatoid Joint
Chrong-Reen Wang¹, Shih-Yao Chen¹, Ai-Li Shiau², Ming-Fei Liu¹ and Chao-Liang Wu³, ¹Internal Medicine, National Cheng Kung University Medical College and Hospital, Tainan, Taiwan, ²Microbiology and Immunology, National Cheng Kung University Medical College, Tainan, Taiwan, ³Biochemistry and Molecular Biology, National Cheng Kung University Medical College, Tainan, Taiwan
Background/Purpose: Apoptosis-resistant synovial fibroblasts (SFs) constitute the major cell component of pannus tissues in rheumatoid arthritis (RA). In tumor cells, the binding of inhibitory…
Abstract Number: 458 • 2016 ACR/ARHP Annual Meeting
The TAM Receptors Axl and Mer Play a Protective Role in a Temporal and Spatial Manner in Inflammatory Arthritis
Claire E.J. Waterborg¹, Paqui G. Través², Silke Beermann¹, Marije I. Koenders¹, Greg Lemke² and Fons A.J. van de Loo¹, ¹Experimental Rheumatology, Radboudumc, Nijmegen, Netherlands, ²Molecular Neurobiology Laboratory, The Salk Institute for Biological Studies, La Jolla, CA
Background/Purpose: Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by an unrestrained inflammatory response in selective, anatomically distinct synovial joints. The innate immune system…
Abstract Number: 2581 • 2016 ACR/ARHP Annual Meeting
Tripterygium Wilfordii Hook F Applied Topically in Patients with Active Rheumatoid Arthritis
Juan Jiao¹, Hai-bo Yin², Xiao-po Tang², Xun Gong² and Quan Jiang¹, ¹Rheumatology Department, Guang’anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China, ²Guang’anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China
Background/Purpose: Tripterygium wilfordii Hook F (TwHF), a traditional Chinese herb, is widely used in China for treating Rheumatoid Arthritis (RA), but limited only for eldly…
Abstract Number: 460 • 2016 ACR/ARHP Annual Meeting
TAS5315, a Novel Bruton’s Tyrosine Kinase Inhibitor, Demonstrates Anti-Inflammatory Effect in Autoimmune Disease Models
Yohei Yoshiga¹, Fumihito Hosoi¹, Satoru Iguchi¹, Ryuusuke Kaneko¹, Yoshinori Nakachi¹, Daichi Akasaka¹, Kenji Tanaka², Kazuhiko Yonekura², Teruhiro Utsugi², Eiji Sasaki² and Yoshikazu Iwasawa², ¹TAIHO PHARMACEUTICAL CO., LTD., TSUKUBA, Japan, ²TAIHO PHARMACEUTICAL CO., LTD., Tsukuba, Japan
Background/Purpose: Bruton’s Tyrosine Kinase (BTK), a non-receptor tyrosine kinase is involved in intracellular signaling pathways downstream of several receptors, including the B cell receptor (BCR),…
Abstract Number: 2656 • 2016 ACR/ARHP Annual Meeting
Resume of Biologic Therapy after Tuberculosis Infection in Patients with Inflammatory Arthropathies. Daily Clinical Practice Data from an Endemic Country
Liliana Uribe Botero¹, Margarita A Saldarriaga Alvarez¹, Natalia Duque Zapata¹, Johnny Urrego¹, Oscar Jair Felipe Diaz¹, Carmen Cerón², Alejandro Uribe¹, Luis Alonso Gonzalez^1,3 and José A. Gómez-Puerta¹, ¹Medicarte IPS, Medellín, Colombia, Medellín, Colombia, ²Medicarte IPS, Medellín, Colombia, ³Rheumatology Unit, Universidad de Antioquia, Medellin, Colombia
Background/Purpose: Long-term extension studies and observational drug registers mainly from Western countries or non-endemic areas have reported an increased risk of tuberculosis (TB) infection in…
Abstract Number: 485 • 2016 ACR/ARHP Annual Meeting
Sexual Dimorphism of Popliteal Lymph Node Collapse As a Biomarker of Disease Progression in the Tumor Necrosis Factor Transgenic Mouse Model of Rheumatoid Arthritis
Emily Wu¹, Richard Bell², Christopher Rudmann³, Ronald Wood⁴, Christopher T. Ritchlin⁵, Homaira Rahimi⁶ and Edward Schwarz⁷, ¹Department of Immunology, Microbiology, and Virology, University of Rochester, Rochester, NY, ²Pathology, University of Rochester, Rochester, NY, ³Biological Sciences, Carnegie Mellon University, Pittsburgh, PA, ⁴University of Rochester, Rochester, NY, ⁵Allergy Immunology & Rheumatology, University of Rochester Medical Center, Rochester, NY, ⁶Rheumatology, University of Rochester/Golisano Children's Hosp, Rochester, NY, ⁷Orthopedeatrics, University of Rochester, Rochester, NY
Background/Purpose: Although rheumatoid arthritis (RA) tends to occur earlier and with increased severity in females, the underling etiology of this sexual dimorphism is unknown. We…
Abstract Number: 3011 • 2016 ACR/ARHP Annual Meeting
Long-Term Outcomes after Disease Activity Guided Tapering of Tumor Necrosis Factor Inhibition in Rheumatoid Arthritis: 3 Year Data of a Randomised Controlled Pragmatic Non Inferiority Strategy Study
Alfons A. den Broeder¹, Chantal A.M. Bouman¹, Frank H.J. van den Hoogen^1,2, Jaap Fransen², Ronald F. van Vollenhoven³, Johannes W.J. Bijlsma⁴, Aatke van der Maas¹ and Noortje van Herwaarden¹, ¹Rheumatology, Sint Maartenskliniek, Nijmegen, Netherlands, ²Rheumatology, Radboud University Medical Center, Nijmegen, Netherlands, ³Amsterdam Rheumatology and Immunology Center ARC, Amsterdam, Netherlands, ⁴Department of Rheumatology and Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands
Long-term Outcomes After Disease Activity Guided Tapering of TNF Inhibitors in Rheumatoid Arthritis: 3 Year Data of a Randomized Controlled Pragmatic Non Inferiority Strategy Study…
Abstract Number: 497 • 2016 ACR/ARHP Annual Meeting
The Identification of an ACR Score with the Optimal Discriminatory Ability Between Treatments in Patients with Early and Established Rheumatoid Arthritis
Josef Smolen¹, Roy Fleischmann², Daniel Aletaha³, Yihan Li⁴, Stefan Florentinus⁴ and Ivan Lagunes Galindo⁴, ¹Medical University of Vienna and Hietzing Hospital, Vienna, Austria, ²Medicine, University of Texas Southwestern Medical Center, Dallas, TX, ³Medical University Vienna and Hietzing Hospital, Vienna, Austria, ⁴AbbVie Inc., North Chicago, IL
Background/Purpose: In patients (pts) with rheumatoid arthritis (RA), the American College of Rheumatology (ACR)20 score was developed to best discriminate effective from placebo…
Abstract Number: 3026 • 2016 ACR/ARHP Annual Meeting
The Efficacy and Safety of Low Dose IL-2 Therapy in over-Treated Patients with Rheumatoid Arthritis: A Preliminary Study
Sheng-Xiao Zhang¹, Miao Miao², Xiao-Qing Liu², Xiao-Wen Ma², Xiao-Yan Wu² and Xiao-Feng Li¹, ¹Rheumatology, The Second Hospital of Shanxi Medical University, Taiyuan, China, ²The Second Hospital of Shanxi Medical University, Taiyuan, China
Background/Purpose: Current therapy for rheumatoid arthritis (RA) often leads to excessive immunosuppression induced by glucocorticoids and DMARDs. Low-dose Interleukin 2 (IL-2) has been showed to induce…
Abstract Number: 575 • 2016 ACR/ARHP Annual Meeting
Differences in Histological Scores and Histoclinical Correlations in ACPA- Versus ACPA+ Rheumatoid Arthritis Patients
Fadil Pirbuccus¹, Christine Galant¹, Adrien Nzeusseu Toukap², Frédéric A. Houssiau¹, Patrick Durez² and Bernard R. Lauwerys¹, ¹Pôle de pathologies rhumatismales inflammatoires et systémiques, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain, Brussels, Belgium, ²Pôle de Maladies Rhumatismales, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain, Brussels, Belgium
Background/Purpose: Differences in the pathogenesis of ACPA- versus ACPA+ rheumatoid arthritis are still poorly understood. In this study, we compared patterns of synovial changes in…
Abstract Number: 3124 • 2016 ACR/ARHP Annual Meeting
Huntingtin Interacting Protein 1 (Hip1) Is a New Arthritis Severity Gene
Teresina Laragione¹, Percio Gulko¹ and Max Brenner², ¹Medicine/Rheumatology, Icahn School of Medicine at Mount Sinai, New York, NY, ²Feinstein Institute for Medical Research, Manhasset, NY
Background/Purpose: Cia25/Pia42 is an arthritis severity and joint damage quantitative trait locus on rat chromosome 12 previously identified in an intercross between MHC identical but…
Abstract Number: 1036 • 2016 ACR/ARHP Annual Meeting
Dominant B-Cell Receptor Clones in Peripheral Blood Predict Onset of Arthritis in Individuals at Risk for Rheumatoid Arthritis
Paul-Peter Tak^1,2,3, Marieke E. Doorenspleet⁴, Maria de Hair⁵, Paul L. Klarenbeek⁶, Marian van Beers-Tas⁷, Antoine H.C. van Kampen⁸, Dirkjan van Schaardenburg^9,10, Danielle M. Gerlag^11,12, Frank Baas¹³ and Niek de Vries¹⁴, ¹Clinical Immunology & Rheumatology F4.105, Amsterdam Rheumatology and Immunology Center, Department of Clinical Immunology & Rheumatology, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands, ²Currently: GlaxoSmithKline, Stevenage, UK, Stevenage, United Kingdom, ³currently: Ghent University, Ghent, Belgium & Cambridge University, Cambridge, United Kingdom, ⁴Dept. of Clinical Immunology & Rheumatology, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands, ⁵Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ⁶Dept. of Clinical Immunology & Rheumatology, Amsterdam Rheumatology and immunology Center | Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands, ⁷Rheumatology, Amsterdam Rheumatology & Immunology Center, Reade, Amsterdam, Netherlands, ⁸Dept Clin Epidemiology, Biostatistics & Bioinformatics, Academic Medical Center/Univ. of Amsterdam, Amsterdam, Netherlands, ⁹Clinical Immunology & Rheumatology F4.105, Amsterdam Rheumatology and immunology Center | Academic Medical Center, Amsterdam, Netherlands, Amsterdam, Netherlands, ¹⁰Rheumatology, Amsterdam Rheumatology and immunology Center, location Reade, Amsterdam, Netherlands, Amsterdam, Netherlands, ¹¹Clinical Immunology & Rheumatology, ARC | Division of Clinical Immunology and Rheumatology, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands, ¹²Current address: GSK,Clinical Unit Cambridge,R&D Projects Clinical Platforms & Sciences, Cambridge, United Kingdom, ¹³Department of Genome Analysis, Academic Medical Center/Univ. of Amsterdam, Amsterdam, Netherlands, ¹⁴Clinical Immunology and Rheumatology, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands
Background/Purpose: The onset of seropositive rheumatoid arthritis (RA) is preceded by the presence of specific autoantibodies in the absence of synovial inflammation. Only a subset…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].